BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 21468257)

  • 1. Clinical significance of a large difference (≥ 2 points) between biopsy and post-prostatectomy pathological Gleason scores in patients with prostate cancer.
    Yoo C; Oh CY; Cho JS; Song C; Seo SI; Ahn H; Hwang TK; Cheon J; Lee KH; Kwon TG; Jung TY; Chung MK; Lee SE; Lee HM; Lee ES; Choi YD; Chung BH; Kim HJ; Kim WJ; Byun SS; Choi HY
    J Korean Med Sci; 2011 Apr; 26(4):507-12. PubMed ID: 21468257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Significance of the Disparity Between Biopsy and Pathologic Gleason Score After Radical Prostatectomy in Clinical Candidates for Active Surveillance According to the Royal Marsden Criteria.
    Jo JK; Hong SK; Byun SS; Lee SE; Lee S; Oh JJ
    Clin Genitourin Cancer; 2016 Aug; 14(4):e329-33. PubMed ID: 26935997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Predictive factors for clinically significant elevation of post-prostatectomy Gleason score in patients with biopsy Gleason score ≤7].
    Guo X; Ma LM; Wu Y; Zhang YP; Li HL; Nong SJ; Guan YB; Huang YQ; Cai B
    Zhonghua Nan Ke Xue; 2018 Dec; 24(12):1094-1099. PubMed ID: 32212489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is the biopsy Gleason score important in predicting outcomes for patients after radical prostatectomy once the pathological Gleason score is known?
    Vira MA; Guzzo T; Heitjan DF; Tomaszewski JE; D'Amico A; Wein AJ; Malkowicz SB
    BJU Int; 2008 May; 101(10):1232-6. PubMed ID: 18419697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
    Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigative clinical study on prostate cancer part IX and X: estradiol and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population after radical prostatectomy.
    Porcaro AB; Ghimenton C; Petrozziello A; Sava T; Migliorini F; Romano M; Caruso B; Cocco C; Antoniolli SZ; Lacola V; Rubilotta E; Monaco C
    Anticancer Res; 2012 Oct; 32(10):4523-32. PubMed ID: 23060581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
    Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
    J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients.
    King CR; McNeal JE; Gill H; Presti JC
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):386-91. PubMed ID: 15145152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations of pretreatment serum total testosterone measurements with pathology-detected Gleason score cancer.
    Porcaro AB; Petrozziello A; Ghimenton C; Migliorini F; Sava T; Caruso B; Romano M; Cavalleri S; Artibani W
    Urol Int; 2014; 93(3):269-78. PubMed ID: 24334919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum total testosterone is a significant preoperative variable independently contributing to separating the prostate cancer population into prostatectomy Gleason score groups.
    Porcaro AB; Petrozziello A; Ghimenton C; Migliorini F; Sava T; Caruso B; Cocco C; Romano M; Cavalleri S; Artibani W
    Urol Int; 2013; 91(1):55-61. PubMed ID: 23751412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients with Biopsy Gleason Score 3 + 4 Are Not Appropriate Candidates for Active Surveillance.
    Park J; Yoo S; Cho MC; Jeong CW; Ku JH; Kwak C; Kim HH; Jeong H
    Urol Int; 2020; 104(3-4):199-204. PubMed ID: 31694041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of clinical outcomes between upgraded pathologic Gleason score 3 + 4 and non-upgraded 3 + 4 prostate cancer among patients who are candidates for active surveillance.
    Jo JK; Hong SK; Byun SS; Lee SE; Oh JJ
    World J Urol; 2015 Nov; 33(11):1729-34. PubMed ID: 25809876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Percentage of cancer in prostate biopsies as prognostic factor for staging and postoperative biochemical failure after radical prostatectomy.
    Villamón-Fort R; Martínez-Jabaloyas JM; Soriano-Sarriá P; Ramos-Soler D; Pastor-Hernández F; Gil-Salom M
    Urol Int; 2007; 78(4):328-33. PubMed ID: 17495491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gleason score concordance on biopsy-confirmed prostate cancer: is pathological re-evaluation necessary prior to radical prostatectomy?
    Truesdale MD; Cheetham PJ; Turk AT; Sartori S; Hruby GW; Dinneen EP; Benson MC; Badani KK
    BJU Int; 2011 Mar; 107(5):749-754. PubMed ID: 20840549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
    J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific Mortality.
    Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
    J Urol; 2017 Apr; 197(4):1060-1067. PubMed ID: 27847296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenocarcinoma of the prostate with Gleason score 9-10 on core biopsy: correlation with findings at radical prostatectomy and prognosis.
    Ellis CL; Partin AW; Han M; Epstein JI
    J Urol; 2013 Dec; 190(6):2068-73. PubMed ID: 23727307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The significance of micro-lymphatic invasion and pathological Gleason score in prostate cancer patients with pathologically organ-confined disease and negative surgical margins after robot-assisted radical prostatectomy.
    Hashimoto T; Nakashima J; Inoue R; Komori O; Yamaguchi Y; Kashima T; Satake N; Nakagami Y; Namiki K; Nagao T; Ohno Y
    Int J Clin Oncol; 2020 Feb; 25(2):377-383. PubMed ID: 31673831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.